Comparison of the effect of amphotericin B desoxycholate and amphotericin B colloidal dispersion on renal functions and renal morphology in rats

Nephrology

Volumn 10, Issue 1, 2005, Pages 57-62

  Doubek, Michael ^a   Mayer, Jiri ^a   Lauschova, Irene ^b   Scheer, Peter ^c   Krejcirova, Lenka ^b   Horky, Drahomir ^b   Doubek, Jaroslav ^c  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

^c UNIVERSITY OF VETERINARY AND PHARMACEUTICAL SCIENCES   (Czech Republic)

Author keywords

Amphotericin B colloidal dispersion; Amphotericin B desoxycholate; Nephrotoxicity; Rat

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B SQUIBB;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DENSITY; CELL VACUOLE; CONTROLLED STUDY; CYTOPLASM; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; GLOMERULUS; GLOMERULUS FILTRATION; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY STRUCTURE; KIDNEY TUBULE; MALE; MITOCHONDRION; MYCOSIS; NEPHROTOXICITY; NONHUMAN; PEROXISOME; PRIORITY JOURNAL; RAT;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; CYTOPLASM; DEOXYCHOLIC ACID; DRUG COMBINATIONS; GLOMERULAR FILTRATION RATE; KIDNEY TUBULES, COLLECTING; KIDNEY TUBULES, PROXIMAL; LOOP OF HENLE; MALE; MITOCHONDRIA; MODELS, ANIMAL; RATS; RATS, WISTAR; VACUOLES;

EID: 14844292620     PISSN: 13205358     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2005.00339.x     Document Type: Article

References (40)

1. Bodey GP (ed). Candidiasis: Pathogenesis, Diagnosis and Treatment, 2nd edn. New York: Raven Press, 1993.
2. Costa S, Nucci M. Can we decrease amphotericin nephrotoxicity? Curr. Opin. Crit. Care 2001; 7: 379-83.
3. Seabury JH, Dascomb HE. Experience with amphotericin B. Ann. N Y Acad. Sci. 1960; 89: 202-20.
4. Fisher MA, Talbot GH, Maislin G et al. Risk factors for amphotericin B-associated nephrotoxicity. Am. J. Med. 1989; 87: 547-52.
5. Llanos A, Cieza J, Bernardo J et al. Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney Int. 1991; 40: 302-8.
6. Prentice HG, Hann IM, Herbrecht R et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br. J. Haematol. 1997; 98: 711-18.
7. Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. 1999; 340: 764-71.
8. Walsh TJ, Hiemenz JW, Seibel NT et al. Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases. Clin. Infect. Dis. 1998; 26: 1383-96.
9. White MH, Bowden RA, Sandler ES et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion versus amphotericin B in the empirical treatment of fever and neutropenia. Clin. Infect. Dis. 1998; 27: 296-302.
10. Tollemar J, Ringdén O. Lipid formulations of amphotericin B. Less toxicity but at what economic cost? Drug Saf. 1995; 13: 207-18.
11. Mayer J, Doubek M, Doubek J et al. Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: Animal experiments and clinical study. J. Infect. Dis. 2002; 186: 379-88.
12. Mayer J, Doubek M, Vorlícek J. Must we really fear toxicity of conventional amphotericin B in oncological patients? Support Care Cancer 1999; 7: 51-5.
13. Sawaya BP, Weihprecht H, Campbell WR et al. Direct vasoconstriction as a possible cause for amphotericin B - induced nephrotoxicity in rats. J. Clin. Invest. 1991; 87: 2097-107.
14. Tolins JP, Raij L. Chronic amphotericin B nephrotoxicity in the rat: Protective effect of prophylactic salt loading. Am. J. Kidney Dis. 1988; 11: 313-17.
15. Butler WT, Bennet JE, Alling DW et al. Nephrotoxicity of amphotericin B. Early and late effects in 81 patients. Ann. Intern. Med. 1964; 61: 175-87.
16. Butler WT, Hill GJ, Szwed CF, Knight V. Amphotericin B renal toxicity in the dog. J. Pharmacol. Exp. Ther. 1963; 143: 47-56.
17. Tolins JP, Raij L. Adverse effect of amphotericin B administration on renal hemodynamics in the rat. Neurohumoral mechanisms and influence of calcium channel blockade. J. Pharmacol. Exp. Ther. 1988; 245: 594-8.
18. Wasan KM, Vadei K, Lopez-Berestein G, Luke DR. Pharmacokinetics, tissue distribution, and toxicity of free and liposomal amphotericin B in diabetic rats. J. Infect. Dis. 1990; 161: 562-6.
19. Cheng J-T, Witty RT, Robinson RR, Yarger WE. Amphotericin B nephrotoxicity: Increased renal resistance and tubule permeability. Kidney Int. 1982; 22: 626-33.
20. Barton CH, Pahl M, Vaziri ND, Cesario T. Renal magnesium wasting associated with amphotericin B therapy. Am. J. Med. 1984; 77: 471-4.
21. Heyman SN, Stillman IE, Brezis M et al. Chronic amphotericin nephropathy: Morphometric, electron microscopic, and functional studies. J. Am. Soc. Nephrol. 1993; 4: 69-80.
22. Sawaya BP, Briggs JP, Schnermann J. Amphotericin B nephrotoxicity: The adverse consequences of altered membrane properties. J. Am. Soc. Nephrol. 1995; 6: 154-64.
23. Walev I, Bhakdi S. Possible reason for preferential damage to renal tubular epithelial cells evoked by amphotericin B. Antimicrob. Agents Chemother. 1996; 40: 1116-20.
24. Späth-Schwalbe E, Koschut A, Dietzmann A et al. Successful use of liposomal amphotericin B in case of amphotericin B-induced nephrogenic diabetes insipidus. Clin. Infect. Dis. 1999; 28: 680-1.
25. Olivero JJ, Lozano-Mendez J, Ghafary EM et al. Mitigation of amphotericin B nephrotoxictty by mannitol. BMJ 1975; 1: 550-1.
26. Hänel H, Schrinner E, Schmidts L. Observations on pentoxifylline/amphotericin B co-treatment in mice. Int. J. Exp. Clin. Chemother. 1991; 4: 205-11.
27. Camp MJ, Wingard JR, Gilmore CE et al. Efficacy of low-dose dopamine in preventing amphotericin B nephrotoxicity in bone marrow transplant patients and leukemia patients. Antimicrob. Agents Chemother. 1998; 42: 3103-6.
28. Soupart A, Decaux G. Nifedipine and amphotericin B nephrotoxicity in the rat. Acta Clin. Belg. 1988; 43 (Suppl. 12): P143.
29. Branch RA, Almgren J, Kern J et al. Prevention of amphotericin B induced renal impairment. Arch. Intern. Med. 1988; 148: 2389-94.
30. Khoo SH, Bond J, Denning DW. Administering amphotericin B - a practical approach. J. Antimicrob. Chemother. 1994; 33: 203-13.
31. Ohnishi A, Ohnishi T, Jackson EK et al. Amelioration of chronic amphotericin B nephrotoxicity in the rat by high salt intake. Clin. Res. 1986; 34: 405A.
32. Bernardo JF, Murakami S, Branch RA, Sabra R. Potassium depletion potentiates amphotericin-B-induced toxicity to renal tubules. Nephron 1995; 70: 235-41.
33. Gerkens JF, Branch RA. The influence of sodium status and furosemide on canine acute amphotericin B toxicity. J. Pharmacol. Exp. Ther. 1980; 214: 306-11.
34. Heidemann HT, Gerkens JF, Spickard WA et al. Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am. J. Med. 1983; 75: 476-81.
35. Branch RA, Jackson EK, Jacqz E. Amphotericin-B nephrotoxicity in humans decreased by sodium supplements with coadministration of ticarcillin or intravenous saline. Klin. Wochenschr. 1987; 65: 500-6.
36. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: Randomised controlled trial. BMJ 2001; 322: 579-82.
37. Echevarría I, Barturen C, Renedo MJ, Trocóniz IF, Dios-Viéitez MC. Comparative pharmacokinetics, tissue distribution, and effects on renal function of novel polymeric formulations of amphotericin B and amphotericin B-desoxycholate in rats. Antimicrob. Agents Chemother. 2000; 44: 898-904.
38. Wasan KM, Vadei K, Lopez-Berestein G et al. Pentoxifylline in amphotericin B toxicity rat model. Antimicrob. Agents Chemother. 1990; 34: 241-4.
39. Joly V, Dromer F, Barge J et al. Incorporation of amphotericin B (AMB) into liposomes alters AMB-induced acute nephrotoxicity in rabbits. J. Pharmacol. Exp. Ther. 1989; 251: 311-16.
40. Randall SR, Adams LG, White MR, DeNicola DB. Nephrotoxicity of amphotericin B administered to dogs in a fat emulsion wersus five percent dextrose solution. Am. J. Vet. Res. 1996; 57: 1054-8.